Advocating for Patients: Letter to the FDA on RP1 Treatment Access

Hundreds of patients, families, and friends have shared their stories with AIM at Melanoma about the urgent need for access to RP1+nivolumab. We are grateful to everyone who contributed. Yesterday, along with several other melanoma organizations, we sent a letter to the FDA urging them to make RP1 available while remaining regulatory issues are addressed.

The full letter is embedded below for your reference. Click on the image to enlarge it, or download the PDF using the link beneath the letter.

Download the PDF here